Evoke Pharma Appoints Benjamin Smeal as Director
Company Announcements

Evoke Pharma Appoints Benjamin Smeal as Director

Evoke Pharma ( (EVOK) ) just unveiled an announcement.

Evoke Pharma, Inc. has appointed Benjamin Smeal as a Class II director with a term expiring at the 2027 annual meeting. Smeal, a seasoned investor with a background in public equities and hedge funds, will serve on key committees, bringing valuable expertise to the board. As part of the non-employee director compensation program, he receives stock options and cash compensation, enhancing the company’s strategic direction and governance.

Learn more about EVOK stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyEvoke Pharma trading halted, volatility trading pause
TheFlyEvoke, EVERSANA announce statistically significant improvement using GIMOTI
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App